Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients... Show more
ROIV's Aroon Indicator triggered a bullish signal on December 16, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 202 similar instances where the Aroon Indicator showed a similar pattern. In of the 202 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on January 13, 2026. You may want to consider a long position or call options on ROIV as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ROIV just turned positive on January 13, 2026. Looking at past instances where ROIV's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ROIV advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ROIV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ROIV broke above its upper Bollinger Band on January 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ROIV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.795) is normal, around the industry mean (30.106). P/E Ratio (1.966) is within average values for comparable stocks, (51.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (322.270).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RSSX | 27.92 | 0.38 | +1.36% |
| Return Stacked US Stks &Gold/BitcoinETF | |||
| ZROZ | 65.43 | 0.70 | +1.08% |
| PIMCO 25+ Year Zero Coupon US Trs ETF | |||
| INDL | 55.09 | 0.46 | +0.84% |
| Direxion Daily MSCI India Bull 2x ETF | |||
| ABLG | 32.54 | 0.05 | +0.15% |
| Abacus FCF International Leaders ETF | |||
| BUFG | 27.74 | -0.06 | -0.22% |
| FT Vest Buffered Allocation Gr ETF | |||
A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To ROIV | 1D Price Change % | ||
|---|---|---|---|---|
| ROIV | 100% | +5.78% | ||
| IMVT - ROIV | 61% Loosely correlated | +1.43% | ||
| XENE - ROIV | 48% Loosely correlated | -2.11% | ||
| CLDX - ROIV | 47% Loosely correlated | +1.01% | ||
| IDYA - ROIV | 47% Loosely correlated | -4.75% | ||
| CRNX - ROIV | 47% Loosely correlated | -1.88% | ||
More | ||||